Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal intelligence from Strategic Transactions.
PDL BioPharma Inc. made public its launch of a hostile bid to acquire Nasdaq-traded Neos Therapeutics Inc. on Oct. 26 for $10.25 in cash per share (a 32% premium to the previous 10-day closing average). Dallas-based Neos announced Oct
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?